Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Ophthotech Corp    OPHT

News SummaryMost relevantAll newsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Ophthotech : Provides Update on Zimura® Complement Programs for Treatment of Eye Diseases

share with twitter share with LinkedIn share with facebook
share via e-mail
09/28/2017 | 08:05pm CEST

By a News Reporter-Staff News Editor at Clinical Trials Week -- Ophthotech Corporation (NASDAQ: OPHT) announced the initiation of an open-label Phase 2a clinical trial of Zimura® (avacincaptad pegol), the Company's complement factor C5 inhibitor, in patients with wet age-related macular degeneration (AMD). Zimura will be administered in combination with Lucentis® (ranibizumab), an anti-vascular endothelial growth factor (anti-VEGF), in patients with wet AMD who have not been previously treated with anti-VEGF drugs. A range of Zimura dosing regimens will be assessed. Clinical trial sites have been identified and activated (see also Ophthotech Corporation).

"We believe that supplementing anti-VEGF therapy with a complement inhibitor such as Zimura may have the potential to further enhance the efficacy of anti-VEGF monotherapy in wet AMD," stated Kourous A. Rezaei, M.D., Senior Vice President of Medical Strategy. "Our earlier Phase 1/2a clinical trial assessing Zimura in combination with Lucentis, while small and uncontrolled, showed intriguing results. A recent peer-reviewed publication from the Journal of Clinical Investigation from Scripps Research Institute provided further support that anti-VEGF therapy upregulates complement activation and therefore that complement inhibition during anti-VEGF therapy may have therapeutic merit. These findings establish a foundation to pursue further development of Zimura in wet AMD."

"We are excited to move the Company forward with opportunities consistent with our overall strategy to develop Zimura for both orphan diseases and larger indications in the back of the eye, such as age-related retinal diseases," stated Glenn P. Sblendorio, Chief Executive Officer and President of Ophthotech.

The Company also announced that it remains on track to initiate two additional Zimura clinical trials before the end of the year. The Company's strategy in orphan indications will be led by a randomized, controlled clinical trial to assess Zimura monotherapy in Stargardt disease, a devastating orphan retinal disease-causing vision loss during childhood or adolescence. The other trial will be an open-label Phase 2a clinical trial evaluating Zimura in combination with anti-VEGF therapy for idiopathic polypoidal choroidal vasculopathy (IPCV), an age-related eye disease. Ophthotech is also planning a Phase 2a clinical trial of Zimura monotherapy for intermediate/posterior non-infectious uveitis, an orphan inflammatory disease of the back of the eye. This trial is planned to initiate in 2018.

Keywords for this news article include: Therapy, Clinical Research, Ophthotech Corporation, Clinical Trials and Studies, Eye Diseases and Conditions, Retinal Diseases and Conditions.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on OPHTHOTECH CORP
09/28 OPHTHOTECH : Provides Update on Zimura® Complement Programs for Treatment of Eye..
09/21 OPHTHOTECH : Provides Update on Zimura Complement Programs for Treatment of Eye ..
09/19 OPHTHOTECH : Provides Update on Zimura® Complement Programs for Treatment of Eye..
09/11 BIOTECHNOLOGY MOVERS : Kura Oncology, Inc., (NASDAQ:KURA) and Ophthotech Corp (N..
08/24 OPHTHOTECH : Announces Results from Third Phase 3 Trial of Fovista® in Wet Age-R..
08/22 OPHTHOTECH : Livforsakringsbolaget Skandia Omsesidigt Has Trimmed Citizens Finan..
08/15 OPHTHOTECH : Announces Results from Third Phase 3 Trial of Fovista in Wet Age Re..
08/14 OPHTHOTECH CORP. : Other Events, Financial Statements and Exhibits (form 8-K)
08/14 OPHTHOTECH : Announces Results from Third Phase 3 Trial of Fovista® in Wet Age-R..
More news
News from SeekingAlpha
09/19 Ophthotech provides update on Zimura complement programs for treatment of eye..
09/08 Roche lampalizumab flop weighs on Ophthotech, down 10%
08/21 OPHTHOTECH : 3 Strikes And It's Out?
08/18 SNIPPET ROUNDUP : Transparency For Straumann But A Black Box For Pfizer
08/16 3 THINGS IN BIOTECH YOU SHOULD LEARN : August 16, 2017
Financials ($)
Sales 2017 76,6 M
EBIT 2017 5,54 M
Net income 2017 6,66 M
Debt 2017 -
Yield 2017 -
P/E ratio 2017 3,28
P/E ratio 2018
Capi. / Sales 2017 1,23x
Capi. / Sales 2018 21,0x
Capitalization 94,5 M
Duration : Period :
Ophthotech Corp Technical Analysis Chart | OPHT | US6837451037 | 4-Traders
Technical analysis trends OPHTHOTECH CORP
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 7
Average target price 3,70 $
Spread / Average Target 41%
EPS Revisions
Glenn P. Sblendorio President & Chief Executive Officer
David R. Guyer Executive Chairman
Keith Westby Chief Operating Officer & Senior Vice President
David F. Carroll Chief Financial Officer & Treasurer
Axel Bolte Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES13.35%106 002
ACTELION23.24%29 919
GENMAB22.08%13 910